Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Clozaril
Active Ingredient: Clozapine 100mg
Dosage Form: Tablet
New Zealand Sponsor: Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer: Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom
Conditions:
? The medicine may only be prescribed by:
– medical practitioners who are vocationally registered under the Health Practitioners Competence Assurance Act 2003 in the branches of psychological medicine or psychiatry; and
– medical practitioners employed as registrars in psychological medicine or psychiatry who are under the supervision
of persons of the kind referred to above.
? Persons prescribing the medicine must comply with the requirements of the New Zealand Guidelines for the Use of Atypical Anti-Psychotic Drugs (Third Edition January 2002), and the requirements of local hospital and health service protocols for the use of clozapine.
Note: This consent is valid for two years from 4 February 2007.
Product: Clozaril
Active Ingredient: Clozapine 25mg
Dosage Form: Tablet
New Zealand Sponsor: Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer: Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United Kingdom
Conditions:
? The medicine may only be prescribed by:
– medical practitioners who are vocationally registered under the Health Practitioners Competence Assurance Act 2003 in the branches of psychological medicine or psychiatry; and
– medical practitioners employed as registrars in psychological medicine or psychiatry who are under the supervision
of persons of the kind referred to above.
? Persons prescribing the medicine must comply with the requirements of the New Zealand Guidelines for the Use of Atypical Anti-Psychotic Drugs (Third Edition January 2002), and the requirements of local hospital and health service protocols for the use of clozapine.
Note: This consent is valid for two years from 4 February 2007.
Dated this 26th day of January 2007.
MARK JACOBS, Acting Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).